Xenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027

X-NOVA2 enrollment has reached approximately 80% of its initial target of 450 patients, which is sufficiently powered to demonstrate a clinically meaningful change in the study’s primary endpoint of HAM-D17. The Company plans to complete the six-week dosing period for patients currently enrolled in the trial and unblind the data. Topline data for X-NOVA2 are now expected in Q1 2027.